TY - JOUR
T1 - Type 2 Myocardial Infarction and Long-Term Mortality Risk Factors
T2 - A Retrospective Cohort Study
AU - Šerpytis, Rokas
AU - Lizaitis, Mindaugas
AU - Majauskienė, Egle
AU - Navickas, Petras
AU - Glaveckaitė, Sigita
AU - Petrulionienė, Žaneta
AU - Valevičienė, Nomeda
AU - Laucevičius, Aleksandras
AU - Chen, Qin M.
AU - Alpert, Joseph S.
AU - Šerpytis, Pranas
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
PY - 2023/5
Y1 - 2023/5
N2 - Introduction: In-hospital risk factors for type 1 myocardial infarction (MI) have been extensively investigated, but risk factors for type 2 MI are still emerging. Moreover, type 2 MI remains an underdiagnosed and under-researched condition. Our aim was to assess survival rates after type 2 MI and to analyze the risk factors for patient prognosis after hospitalization. Methods: We conducted a retrospective database analysis of patients with MI diagnosis who were treated in Vilnius University Hospital Santaros Klinikos. A total of 6495 patients with the diagnosis of MI were screened. The primary study endpoint was long-term all-cause mortality. The predictive value of laboratory tests was estimated including blood hemoglobin, D dimer, creatinine, brain natriuretic peptide (BNP), C-reactive protein (CRP), and troponin levels. Results: Out of all the patients diagnosed with MI there were 129 cases of type 2 MI (1.98%). Death rate almost doubled from 19.4% at 6 months to 36.4% after 2 years of follow-up. Higher age and impaired kidney function were risk factors for death both during hospitalization and after 2 years of follow-up. Lower hemoglobin (116.6 vs. 98.9 g/L), higher creatinine (90 vs. 161.9 μmol/L), higher CRP (31.4 vs. 63.3 mg/l), BNP (707.9 vs. 2999.3 ng/L), and lower left ventricle ejection fraction were all predictors of worse survival after 2 years of follow-up. Preventive medication during hospitalization can decrease the mortality risk: angiotensin-converting enzyme inhibitor (ACEi) (HR 0.485, 95% CI 0.286–0.820) and statins (HR 0.549, 95% CI 0.335–0.900). No significant influence was found for beta blockers (HR 0.662, 95% CI 0.371–1.181) or aspirin (HR 0.901, 95% CI 0.527–1.539). Conclusions: There is significant underdiagnosis of type 2 MI (1.98% out of all MIs). If the patient is prescribed a preventive medication like ACEi or statins, the mortality risk is lower. Increased awareness of elevation of laboratory results could help to improve the treatment of these patients and identify the most vulnerable groups.
AB - Introduction: In-hospital risk factors for type 1 myocardial infarction (MI) have been extensively investigated, but risk factors for type 2 MI are still emerging. Moreover, type 2 MI remains an underdiagnosed and under-researched condition. Our aim was to assess survival rates after type 2 MI and to analyze the risk factors for patient prognosis after hospitalization. Methods: We conducted a retrospective database analysis of patients with MI diagnosis who were treated in Vilnius University Hospital Santaros Klinikos. A total of 6495 patients with the diagnosis of MI were screened. The primary study endpoint was long-term all-cause mortality. The predictive value of laboratory tests was estimated including blood hemoglobin, D dimer, creatinine, brain natriuretic peptide (BNP), C-reactive protein (CRP), and troponin levels. Results: Out of all the patients diagnosed with MI there were 129 cases of type 2 MI (1.98%). Death rate almost doubled from 19.4% at 6 months to 36.4% after 2 years of follow-up. Higher age and impaired kidney function were risk factors for death both during hospitalization and after 2 years of follow-up. Lower hemoglobin (116.6 vs. 98.9 g/L), higher creatinine (90 vs. 161.9 μmol/L), higher CRP (31.4 vs. 63.3 mg/l), BNP (707.9 vs. 2999.3 ng/L), and lower left ventricle ejection fraction were all predictors of worse survival after 2 years of follow-up. Preventive medication during hospitalization can decrease the mortality risk: angiotensin-converting enzyme inhibitor (ACEi) (HR 0.485, 95% CI 0.286–0.820) and statins (HR 0.549, 95% CI 0.335–0.900). No significant influence was found for beta blockers (HR 0.662, 95% CI 0.371–1.181) or aspirin (HR 0.901, 95% CI 0.527–1.539). Conclusions: There is significant underdiagnosis of type 2 MI (1.98% out of all MIs). If the patient is prescribed a preventive medication like ACEi or statins, the mortality risk is lower. Increased awareness of elevation of laboratory results could help to improve the treatment of these patients and identify the most vulnerable groups.
KW - Acute cardiovascular events
KW - BNP
KW - Cardiovascular outcomes
KW - Troponin
KW - Type 2 myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85151560068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151560068&partnerID=8YFLogxK
U2 - 10.1007/s12325-023-02485-2
DO - 10.1007/s12325-023-02485-2
M3 - Article
C2 - 37017913
AN - SCOPUS:85151560068
SN - 0741-238X
VL - 40
SP - 2471
EP - 2480
JO - Advances in Therapy
JF - Advances in Therapy
IS - 5
ER -